JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Danaher Corp

Fechado

SetorSaúde

205.97 1.36

Visão Geral

Variação de preço das ações

24h

Atual

Mín

205.26

Máximo

206.14

Indicadores-chave

By Trading Economics

Rendimento

-132M

954M

Vendas

-797M

5.7B

P/E

Médio do Setor

36.377

38.156

EPS

1.88

Rendimento de Dividendos

0.59

Margem de lucro

16.617

Funcionários

61,000

EBITDA

367M

1.8B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+16.62% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.59%

2.50%

Próximos Ganhos

21 de out. de 2025

Próxima data de dividendos

24 de out. de 2025

Próxima data de ex-dividendo

26 de set. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-13B

135B

Abertura anterior

204.61

Fecho anterior

205.97

Sentimento de Notícias

By Acuity

45%

55%

134 / 375 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Danaher Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de jul. de 2025, 11:32 UTC

Ganhos

Danaher Posts Lower 2Q Profit, Names Next CFO -- Update

22 de jul. de 2025, 10:42 UTC

Ganhos

Danaher Posts Higher 2Q Sales, Lower Profit

22 de abr. de 2025, 10:34 UTC

Ganhos

Danaher 1Q Results Decline But Top Estimates

5 de fev. de 2025, 12:54 UTC

Ganhos

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 de jan. de 2025, 11:44 UTC

Ganhos

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 de jul. de 2025, 10:03 UTC

Ganhos

Danaher Had Seen 2025 Adjusted EPS $7.60-$7.75 >DHR

22 de jul. de 2025, 10:03 UTC

Ganhos

Danaher Raises 2025 View To Adj EPS $7.70-Adj EPS $7.80 >DHR

22 de jul. de 2025, 10:02 UTC

Ganhos

Danaher Still Sees 2025 Core Revenue Up About 3% >DHR

22 de jul. de 2025, 10:01 UTC

Ganhos

Danaher Sees 3Q Core Revenue Up Low-Single Digits >DHR

22 de jul. de 2025, 10:00 UTC

Ganhos

Danaher 2Q Operating Cash Flow $1.3B, Free Cash Flow $1.1B >DHR

22 de jul. de 2025, 10:00 UTC

Ganhos

Danaher 2Q Net $555M >DHR

22 de jul. de 2025, 10:00 UTC

Ganhos

Danaher 2Q Sales $5.9B >DHR

22 de jul. de 2025, 10:00 UTC

Ganhos

Danaher 2Q Adj EPS $1.80 >DHR

22 de jul. de 2025, 10:00 UTC

Ganhos

Danaher 2Q EPS 77c >DHR

22 de jul. de 2025, 09:34 UTC

Ações em Alta

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

14 de jul. de 2025, 16:12 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

22 de abr. de 2025, 10:02 UTC

Ganhos

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 de abr. de 2025, 10:02 UTC

Ganhos

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 de abr. de 2025, 10:02 UTC

Ganhos

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 de abr. de 2025, 10:01 UTC

Ganhos

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 de abr. de 2025, 10:01 UTC

Ganhos

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 de abr. de 2025, 10:00 UTC

Ganhos

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

22 de abr. de 2025, 10:00 UTC

Ganhos

Danaher 1Q Adj EPS $1.88 >DHR

22 de abr. de 2025, 10:00 UTC

Ganhos

Danaher 1Q EPS $1.32 >DHR

22 de abr. de 2025, 10:00 UTC

Ganhos

Danaher 1Q Sales $5.74B >DHR

22 de abr. de 2025, 10:00 UTC

Ganhos

Danaher 1Q Net $954M >DHR

29 de jan. de 2025, 15:25 UTC

Conversa de Mercado
Ganhos

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 de jan. de 2025, 13:56 UTC

Principais Notícias
Ganhos

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 de jan. de 2025, 11:08 UTC

Ganhos

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 de jan. de 2025, 11:07 UTC

Ganhos

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

Comparação entre Pares

Variação de preço

Danaher Corp Previsão

Preço-alvo

By TipRanks

16.62% parte superior

Previsão para 12 meses

Média 239.64 USD  16.62%

Máximo 275 USD

Mínimo 205 USD

Com base em 16 analistas de Wall Street que oferecem metas de preço de 12 meses para Danaher Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

16 ratings

14

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

189.8851 / 196.5Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

134 / 375 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.